Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update

by · The Cerbat Gem

Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totalling 88,100 shares, a decrease of 27.8% from the March 15th total of 122,000 shares. Based on an average daily volume of 89,800 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.2% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Alpha Tau Medical in a research note on Monday, March 17th.

Check Out Our Latest Analysis on DRTS

Institutional Investors Weigh In On Alpha Tau Medical

A number of institutional investors have recently made changes to their positions in DRTS. Renaissance Technologies LLC boosted its stake in Alpha Tau Medical by 188.7% during the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company’s stock valued at $127,000 after purchasing an additional 26,800 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Alpha Tau Medical by 112.6% during the fourth quarter. Northern Trust Corp now owns 48,666 shares of the company’s stock valued at $151,000 after purchasing an additional 25,770 shares in the last quarter. Finally, Levin Capital Strategies L.P. boosted its position in shares of Alpha Tau Medical by 2.3% during the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company’s stock valued at $975,000 after buying an additional 7,189 shares during the last quarter. Hedge funds and other institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Stock Up 1.6 %

Shares of DRTS stock traded up $0.04 during trading hours on Friday, hitting $2.57. 4,025 shares of the company’s stock traded hands, compared to its average volume of 48,335. The stock’s fifty day simple moving average is $2.69 and its two-hundred day simple moving average is $2.83. Alpha Tau Medical has a 12-month low of $1.75 and a 12-month high of $4.39. The stock has a market cap of $180.88 million, a price-to-earnings ratio of -5.98 and a beta of 0.93.

Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.13). On average, equities analysts forecast that Alpha Tau Medical will post -0.45 earnings per share for the current fiscal year.

About Alpha Tau Medical

(Get Free Report)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.

Recommended Stories